Biopharma firm Zentalis secures $85m in Series C round

Biopharma firm Zentalis secures $85m in Series C round

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical firm focused on small molecule therapeutics for cancer treatment, has secured $85 million in a Series C round of financing to accelerate the internally developed clinical-stage oncology pipeline.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter